Original Source(s)
Related Content
Atsena Reports LIGHTHOUSE data at ARVO
Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The data were presented at the 2025 Association for Research in Vision and Ophthalmology meeting in Salt Lake City, Utah.
May 1, 2025
-
3 min
Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease
At ARVO 2026, Ikarovec presented 4 posters showcasing its bicistronic platform that combines neuroprotection and complement modulation.
May 1, 2026
-
3 min
